Results 121 to 130 of about 6,788,828 (423)

Dose–Volume and Radiobiological Model-Based Comparative Evaluation of the Gastrointestinal Toxicity Risk of Photon and Proton Irradiation Plans in Localized Pancreatic Cancer Without Distant Metastasis

open access: yesFrontiers in Oncology, 2020
Background: Radiobiological model-based studies of photon-modulated radiotherapy for pancreatic cancer have reported reduced gastrointestinal (GI) toxicity, although the risk is still high. The purpose of this study was to investigate the potential of 3D-
Vijay P. Raturi   +17 more
doaj   +1 more source

Eccrine poromatosis following chemotherapy and radiation therapy [PDF]

open access: yes, 2019
Eccrine poroma presents as a single, symptomless erythematous papule in areas with a high density of eccrine sweat glands. Although rare, eccrine poromas can present as multiple lesions, otherwise known as eccrine poromatosis.
Chiu, Melvin, Kim, Gene, Nguyen, Khoa
core  

Towards Laser Driven Hadron Cancer Radiotherapy: A Review of Progress [PDF]

open access: yes, 2014
It has been known for about sixty years that proton and heavy ion therapy is a very powerful radiation procedure for treating tumours. It has an innate ability to irradiate tumours with greater doses and spatial selectivity compared with electron and ...
Bolton, P. R.   +3 more
core   +3 more sources

Study on neutron radiation field of carbon ions therapy [PDF]

open access: yes, 2015
Carbon ions offer significant advantages for deep-seated local tumors therapy due to their physical and biological properties. Secondary particles, especially neutrons caused by heavy ion reactions should be carefully considered in treatment process and radiation protection.
arxiv   +1 more source

Comparative single‐cell transcriptomic profiling of patient‐derived renal carcinoma cells in cellular and animal models of kidney cancer

open access: yesFEBS Open Bio, EarlyView.
We generated and characterized clear cell renal cell carcinoma models using the patient‐derived RCC243 cell line—including cell culture, orthotopic, and metastatic tumors—via single‐cell RNA‐sequencing for comparisons between models and patient tumor datasets.
Richard Huang   +9 more
wiley   +1 more source

Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline.

open access: yesPractical Radiation Oncology, 2022
V. Gondi   +19 more
semanticscholar   +1 more source

The report of Task Group 100 of the AAPM: Application of risk analysis methods to radiation therapy quality management.

open access: yesMedical Physics (Lancaster), 2016
The increasing complexity of modern radiation therapy planning and delivery challenges traditional prescriptive quality management (QM) methods, such as many of those included in guidelines published by organizations such as the AAPM, ASTRO, ACR, ESTRO ...
M. Huq   +11 more
semanticscholar   +1 more source

Proton therapy- the modality of choice for future radiation therapy management of Prostate Cancer?

open access: yesTechnical Innovations & Patient Support in Radiation Oncology, 2019
Background: Proton Therapy (PR) is an emerging treatment for prostate cancer (Pca) patients. However, limited and conflicting data exists regarding its ability to result in fewer bladder and rectal toxicities compared to Photon Therapy (PT), as well as ...
Sophie Mangan, Michelle Leech
doaj  

Feasibility of surface guided radiotherapy for patient positioning in breast radiotherapy versus conventional tattoo-based setups- a systematic review

open access: yesTechnical Innovations & Patient Support in Radiation Oncology, 2022
Background: Traditionally tattoos are used for patient setup in radiotherapy. However they may pose challenges for the radiotherapists to achieve precise patient alignment, and serve as a permanent visual reminder of the patient’s diagnosis and often ...
Wesley Naidoo, Michelle Leech
doaj  

Adenosine A3 receptor antagonists as anti‐tumor treatment in human prostate cancer: an in vitro study

open access: yesFEBS Open Bio, EarlyView.
The A3 adenosine receptors (A3ARs) are overexpressed in prostate cancer. AR 292 and AR 357, as A3AR antagonists, are capable of blocking proliferation, modulating the expression of drug transporter genes involved in chemoresistance, ferroptosis, and the hypoxia response, and inducing cell death.
Maria Beatrice Morelli   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy